Description
Aniridia is an eye disorder that is characterized by a complete or partial absence of the colored part of the eye (the iris). Aniridia is typically present from birth (congenital) and affects both eyes. The pupils may also be abnormal or misshapen.
People with aniridia can have other eye problems that may be congenital or develop later in life. Clouding of the lenses of the eyes (cataracts
) occurs in most people with aniridia. Affected individuals often have involuntary eye movements (nystagmus) or an increased sensitivity to light (photophobia). Underdevelopment of a specific region at the back of the eye (foveal hypoplasia) can reduce the sharpness of vision (visual acuity).
Additional signs and symptoms of aniridia may include problems with the cornea (aniridia-associated keratopathy). The cornea is the clear outer covering of the eye. Aniridia can also cause increased pressure in the eye (glaucoma
) in late childhood through early adulthood. In some affected individuals, the structures that carry information from the eyes to the brain are underdeveloped (optic nerve hypoplasia). Many of these eye problems contribute to vision loss that worsens over time. The severity of symptoms is typically the same in both eyes.
In rare cases, individuals with aniridia have additional health problems, which can include behavioral issues, metabolic disorders, and problems detecting odors.
Aniridia can affect the eyes alone (isolated) or it can occur with other features as part of a syndrome. Aniridia is a common feature of certain genetic conditions including Gillespie syndrome and WAGR syndrome.
Injuries to the head or eyes can also cause aniridia. This type of aniridia is not genetic and can occur at any age.
Frequency
Aniridia occurs in 1 in 40,000 to 100,000 newborns worldwide.
Causes
Genetic changes that cause disease are called pathogenic variants. Pathogenic variants in the PAX6 gene can cause aniridia. The PAX6 gene provides instructions for making a protein that is involved in the early development of the eyes, brain and spinal cord (central nervous system), and the pancreas. The PAX6 protein belongs to a group of proteins called transcription factors. These proteins bind to specific regions of DNA and regulates the activity of other genes. After birth, the PAX6 protein is found in many different eye structures
, where it regulates gene activity.
Pathogenic variants in the PAX6 gene cause cells to produce a nonfunctional PAX6 protein that is unable to bind to DNA and regulate the activity of other genes. Without enough functional PAX6 protein, the formation of the eyes is disrupted before birth, leading to the various signs and symptoms of aniridia.
In a small percentage of cases, aniridia can be caused by pathogenic variants in other genes. These genes produce proteins that control the expression of the PAX6 gene. Pathogenic variants in these genes lead to a reduction in PAX6 protein activity, much like variants in the PAX6 gene.
When aniridia is part of a syndrome, it is caused by gene variants associated with that syndrome.
Inheritance
Aniridia is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In approximately two-thirds of cases, a person with aniridia inherits the pathogenic variant from one affected parent
. The remaining one-third of cases result from a new (de novo) variant
in the gene that occurs during the formation of reproductive cells (eggs or sperm) in an affected individual's parent or during early embryonic development. These affected individuals typically have no history of the disorder in their family.
Other Names for This Condition
- Absent iris
- Congenital aniridia
- Irideremia
Additional Information & Resources
Genetic Testing Information
Genetic and Rare Diseases Information Center
Patient Support and Advocacy Resources
Clinical Trials
Catalog of Genes and Diseases from OMIM
Scientific Articles on PubMed
References
- Chao LY, Huff V, Strong LC, Saunders GF. Mutation in the PAX6 gene in twenty patients with aniridia. Hum Mutat. 2000;15(4):332-9. doi: 10.1002/(SICI)1098-1004(200004)15:43.0.CO;2-1. Citation on PubMed
- Grainger RM, Lauderdale JD, Collins JL, Trout KL, McCullen Krantz S, Wolfe SS, Netland PA. Report on the 2021 Aniridia North America symposium on PAX6, aniridia, and beyond. Ocul Surf. 2023 Jul;29:423-431. doi: 10.1016/j.jtos.2023.05.010. Epub 2023 May 27. Citation on PubMed
- Hall J, Corton M, Fries FN, Obst J, Grunauer-Kloevekorn C, Seitz B, Waizel MDV, Javorszky E, Tory K, Maka E, Amini M, Suiwal S, Stachon T, Szentmary N. Comprehensive Analysis of Congenital Aniridia and Differential Diagnoses: Genetic Insights and Clinical Manifestations. Ophthalmol Ther. 2025 May;14(5):835-856. doi: 10.1007/s40123-025-01122-1. Epub 2025 Mar 26. Citation on PubMed
- Kit V, Cunha DL, Hagag AM, Moosajee M. Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia. JCI Insight. 2021 Jul 22;6(14):e148406. doi: 10.1172/jci.insight.148406. Citation on PubMed
- Lee H, Khan R, O'Keefe M. Aniridia: current pathology and management. Acta Ophthalmol. 2008 Nov;86(7):708-15. doi: 10.1111/j.1755-3768.2008.01427.x. Epub 2008 Oct 6. Citation on PubMed
- Moosajee M, Hingorani M, Moore AT. PAX6-Related Aniridia. 2003 May 20 [updated 2018 Oct 18]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1360/ Citation on PubMed
- Robinson DO, Howarth RJ, Williamson KA, van Heyningen V, Beal SJ, Crolla JA. Genetic analysis of chromosome 11p13 and the PAX6 gene in a series of 125 cases referred with aniridia. Am J Med Genet A. 2008 Mar 1;146A(5):558-69. doi: 10.1002/ajmg.a.32209. Citation on PubMed
The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.